Paul Tudor Jones Catalyst Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 76,088 shares of CPRX stock, worth $1.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,088
Previous 61,586
23.55%
Holding current value
$1.6 Million
Previous $1.49 Million
10.58%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$393 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$115 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$68.3 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$66.9 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...